Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04887870
Title Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.

Advanced Solid Tumor


Ipilimumab + Sitravatinib

Nivolumab + Sitravatinib

Enfortumab vedotin-ejfv + Sitravatinib

Pembrolizumab + Sitravatinib


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.